Preventing Adverse Drug Events With PatientSite
This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care. We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' ability to detect adverse drug events among primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Prevention
|Official Title:||Preventing Adverse Drug Events With PatientSite|
- To prevent adverse drug events with PatientSite. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- Improve patient satisfaction [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- better utilization of services [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- improve patient-clinician communication [ Time Frame: 3 years ] [ Designated as safety issue: No ]
|Study Start Date:||April 2003|
|Study Completion Date:||December 2004|
|Primary Completion Date:||December 2004 (Final data collection date for primary outcome measure)|
Electronic medication safety queries via PatientSite portal
Other: Medcheck message
Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
No Intervention: Usual care
No electronic medication safety messages via PatientSite portal
- A drug safety module called MedCheck was developed for PatientSite. This allows physicians to query patients automatically 10 days after they receive a new prescription asking them questions about their new prescription. In this study new enhancements will be tested.
- Participants will be assigned at random to the intervention group or control group. The intervention group will receive a single electronic PatientSite message asking them questions about the new prescription which is then forwarded to their physician. The control group will receive a generic message about medication safety.
- To identify adverse drug events, a telephone survey and medical record review will be conducted of patients in the intervention group and controls.
- This study will run for 12 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00140504
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Saul N Weingart, MD, PhD||Dana-Farber Cancer Institute|